Last Friday, Merck released a final analysis of its clinical trial for molnupiravir, their COVID-19 antiviral pill. An interim analysis stated molnupiravir reduced the risk of hospitalization and death by 50%; it has now been lowered to 30%.
Read More »Last Friday, Pfizer announced that the clinical trial for their COVID-19 antiviral pill, Paxlovid, demonstrated high efficacy in preventing severe COVID-19 in at-risk persons. Paxlovid is unique and differs from Merck’s COVID-19 antiviral, Molnupiravir, by binding to enzymes responsible for the replication of SARS-CoV-2 and inhibiting its life cycle.
Read More »Last Thursday, the UK became the first country to approve an antiviral drug for COVID-19. Molnupiravir, developed by Merck and Ridgeback Biotherapeutics, is designed to stop SARS-CoV-2 from replicating by disrupting its genetic code.
Read More »This morning, the pharmaceutical company Merck submitted an application for EUA of their COVID-19 oral antiviral pill. If accepted, this will become the first pill authorized by the FDA to treat COVID-19. Other FDA authorized COVID-19 treatments must be administered intravenously or via injection.
Read More »